INCMGA00012

Phase 3Small molecule

Incyte

INCMGA00012 is one of 108 small molecule programs targeting Cancer of the Head and Neck. It is currently in Phase 3.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of the Head and NeckActive, not recruiting

GlioblastomaActive, not recruiting

HIVActive, not recruiting

Concurrent ChemoradiotherapyActive, not recruiting

Neoadjuvant ChemotherapyRecruiting

Cancer of the Head and NeckPhase 1

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

HIVPhase 3

Active, not recruiting

Concurrent ChemoradiotherapyPhase 2

Active, not recruiting

Neoadjuvant ChemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

160 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

58 2

Keytruda

Merck & Co.

Phase 3

24 3

Opdivo

Bristol-Myers Squibb

Phase 3

18 4

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Yervoy

11 6

Ceenu

AAzurity Pharmaceuticals

Phase 3

21 7

Antabuse

Teva

Phase 3

5 8

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Concurrent Chemoradiotherapy

NCT04494009

Q2 2027

Phase 2Active, not recruiting

Well-Differentiated/dedifferentiated Liposarcoma

NCT04438824

Q4 2027

Phase 2Recruiting

Neoadjuvant Chemotherapy

NCT04968106

Q4 2028

Phase 1Active, not recruiting

Cancer of the Head and Neck

NCT04470024

Clinical

Trials by Indication[1]

Advanced Malignancies1 trial

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1·NCT03522142·83 enrolled

Concurrent Chemoradiotherapy1 trial

PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Active, not recruiting·—·Phase 2·NCT04494009·110 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Recruiting·IInstitut Bergonié·Phase 2·NCT04968106·66 enrolled

Ampullary Cancer1 trial

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04116073·25 enrolled

Well-differentiated/Dedifferentiated Liposarcoma1 trial

A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04438824·42 enrolled

4 more indications

Cancer of the Head and Neck1 trial

A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT04470024·19 enrolled

Melanoma1 trial

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Completed· Incyte logo

Incyte·Preclinical·NCT04370704·61 enrolled

Glioblastoma1 trial

A Phase II Study of the Anti-GITR Agonist INCAGN1876 and the PD-1 Inhibitor INCMGA00012 in Combination With Stereotactic Radiosurgery in Recurrent Glioblastoma

Active, not recruiting·UUniversity of Pennsylvania·Phase 2·NCT04225039·39 enrolled

HIV1 trial

ATLAS-2M Extension: Cabotegravir LA for PrEP

Active, not recruiting· GSK logo

GSK·Phase 3·NCT04580485·1,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for INCMGA00012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCMGA00012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCMGA00012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

INCMGA00012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Advanced Malignancies1 trial

Concurrent Chemoradiotherapy1 trial

Neoadjuvant Chemotherapy1 trial

Ampullary Cancer1 trial

Well-differentiated/Dedifferentiated Liposarcoma1 trial

Cancer of the Head and Neck1 trial

Melanoma1 trial

Glioblastoma1 trial

HIV1 trial

References

Drug Info

Quick Facts

Related News